PUB031 Research on Clinical Effect and Cytokines Dynamic Change of Patient with Advanced Malignant Tumor Treated by PD-1 Inhibitors

G. Zhang,J. Xiang,Y. Xia,Y. Hu

DOI: https://doi.org/10.1016/j.jtho.2017.09.1894

IF: 20.121

2017-01-01

Journal of Thoracic Oncology

Abstract:PD-1 inhibitors have made breakthrough in the treatment of advanced tumors, but there is no comprehensive understanding of the biomarker related to the clinical effect of PD-1 inhibitors. So we have conducted cytokines detection on patients receiving PD-1 inhibitors treatment and analyzed the possible relation between the dynamic changes and the clinical effect. 146 malignant tumor patients receiving Nivolumab or Pembrolizumab for multi-line therapy in our center from January 2015 to January 2017 were collected. And 33 of them took the peripheral blood cytokines test and 35 healthy volunteers are detected as normal control. The short-time survival analysis was made after the first cycle treatment, and the clinical effect reached PR 20 cases (13.7%), SD 102 cases (69.9%), PD 24 cases (16.4%).The ORR was 13.7% and the DCR was 83.6%. Up to the end of follow-up, the median PFS was 4.1 months (95%CL: 3.1-5.0) and the median OS was 11.1 months (95%CL: 8.9-13.2). The initial serum concentration of IL-2, IL-7, Basic FGF, GM-CSF and PDGF-bb in the normal control groups is obviously higher than that of advanced tumor patients, and the initial serum concentration of IL-5, IL-6, IL-8, IL-15, IP-10, MIP-1a, MIP-1b and TNF-a in the advanced tumor patients is obviously higher than that of normal control group. The concentration of IL-10 and IP-10 upon the progress of PD-1 inhibitors treatment is obviously higher than before. The concentration of Eotaxin in the disease control group one cycle after PD-1 inhibitors treatment is obviously higher than that of the progress group; upon three cycles of treatment, the concentration of IL-6 and IL-8 in the progress group is obviously higher than the disease control group. It can be found during the course of 3-cycle and 6-cycle treatment that: cytokines, including IL-1b, IL-6, IL-8, IL-9, MIP-1a and MIP-1β rather steadily change in PR+SD group and fluctuate greatly and even rise sharply in PD group; IL-1ra, IL-2 and IL-15 show crosscurrent, which means they are on the rise in PR+SD group while overall change steadily or lower in PD group. Malignant tumor patients after multi-line therapy can benefit from the PD-1 inhibitors and the concentration change of some peripheral blood cytokines may related to the clinical effect of PD-1 inhibitors. The increase in the cytokines, including IL-1ra, IL-2 and IL-15 may hint better clinical effect; however, the increase in cytokines such as IL-1b, IL-6, IL-8, IL-9, MIP-1a and MIP-1β may hint poorer clinical effect of PD-1 inhibitor treatment.